期刊文献+

奥施康定联合康莱特注射液治疗中晚期癌痛的疗效观察 被引量:4

下载PDF
导出
摘要 疼痛是中、晚期癌症患者的主要症状之一,疼痛不仅引起患者躯体的不适,同时对患者的精神、心理、社会等方面也产生负面影响。疼痛的控制是改善癌症患者生存质量的重要内容,WHO已将控制疼痛列为第三种抗癌治疗手段[1]。本科应用奥施康定联合康莱特注射液治疗中晚期癌痛患者,现对其临床疗效进行评价。报告如下。
作者 林德荣
出处 《浙江临床医学》 2014年第6期941-942,共2页 Zhejiang Clinical Medical Journal
  • 相关文献

参考文献9

  • 1Giovanni A, Oscar B, Augusto C,et al. Pain in cancer.Anoutcome research project to eva luate the epidemio-logy,the quality and the effects of pain treatment in cancer patients.Health and Quality of Life Outcomes, 2006, 4(7):1186-1477.
  • 2王宏羽编.癌症疼痛缓解及姑息性治疗.北京:人民卫生出版社,2005:52.
  • 3赵玉华,倪慧.复方苦参注射液联合羟考酮缓释片治疗中晚期癌痛的疗效观察[J].临床合理用药杂志,2013,6(25):52-53. 被引量:6
  • 4李小梅,刘端祺,李红英,王艳梅.恶性肿瘤患者临终前的阿片类药物止痛回顾[J].中国肿瘤临床,2005,32(23):1358-1360. 被引量:36
  • 5Czamecki M LJandrisevits M D,Theiler SC,et al.Controlled-release oxycodone for he manage ment of pediatric post operative pain.J Pain Symp Manage,2011,27(4):379 -86.
  • 6Watson C P,Moulin D,Watt Watson J,et al.Control led release oxycodone relieves neuropathic pain :arandomized controlled trial in painful diabetic neuropathy. Pain,2013,105(1-2) :71-78.
  • 7Yasui W,Akama Y,Yokozaki H. Expression of p21 WAF-1/CIPL in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression.Pathol Int,2012,47 (7) :470-477.
  • 8Natsugce S,Nakashima S,Matsumoto M. Expression of p21 WAFI / CIP1 in the p53-dependent pathway is related to prognossion in patients tll advanced esophageal car-cinoma .Clin Cancer Res,2009,5 (9) :2445-2449.
  • 9丁延军.康莱特注射液治疗晚期癌痛临床观察[J].滨州医学院学报,2002,25(3):211-211. 被引量:1

二级参考文献13

  • 1Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer [J]. N EnglJ Med, 1994, 330(9): 592-596
  • 2Pargeon KL, Hailey BJ. Barriers to effective cancer pain management: a review of the literature[J].J Pain Symptom Manage, 1999,18(5):358-368
  • 3Berger A, Dukes E, Smith M, et al. Use of oral and transdermal opioids among patients with metastatic cancer during the last year of life[J].J Pain Symptom Manage, 2003, 26(2): 723-730
  • 4Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium[J]. Drugs, 2001, 61(7): 955-977
  • 5Broomhead A, Kerr R, Tester W, et al. Comparison of a oncea-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain [J]. J Pain Symptom Manage,1997, 14(2): 63-73
  • 6Kest B, Sarton E, Dahan A. Gender differences in opioid-mediated analgesia: animal and human studies [J]. Anesthesiology, 2000,93(2): 539-547
  • 7Sarton E, Olofsen E, Romberg R, et al. Sex differences in morphine analgesia: an experimental study in healthy volunteers [J].Anesthesiology, 2000, 93 (5): 1245-1254
  • 8Fillingim RB, Gear RW. Sex differences in opioid analgesia: clinical and experimental findings[J]. EurJ Pain, 2004, 8(5): 413-425
  • 9Vigano A, Bruera E, Suarez-Almazor ME. Age, pain intensity,and opioid dose in patients with advanced cancer [J]. Cancer,1998, 83(6): 1244-1250
  • 10Bercovitch M, Adunsky A. Patterns of high-dose morphine use in a home-care hospice service: should we be afraid of it[J]?Cancer, 2004, 101(6): 1473-1477

共引文献40

同被引文献116

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部